Abstract Oligoribonucleotide conjugates carrying nuclear localization peptide sequences at the 3 -end were prepared stepwise on a single support. The siRNA duplex carrying the nuclear localization peptide sequence at the 3 -end of the passenger strand has similar inhibitory properties as those of unmodified or cholesterol-modified RNA duplexes.
Introduction
In the last two decades new compounds comprising small synthetic nucleic acids have shown promising results as potential drugs [1, 2] . In these cases, nucleic acids are used to inhibit a specific gene by blocking translation or transcription or by stimulating the degradation of a particular messenger RNA. Several strategies can be followed. In the antisense strategy, synthetic oligonucleotides complementary to the messenger RNA of a given gene are used to inhibit the translation of messenger RNA to protein [3, 4] . In the siR-NA strategy, small RNA duplexes complementary to messenger RNA bind to a protein complex named RISC. The complex formed by the antisense or guide RNA strand and RISC catalyzes the efficient degradation of a specific messenger RNA, thereby lowering the amount of target protein [5, 6] .
Some of the problems encountered during the development of nucleic acids as drugs entail the degradation of these by exonucleases under physiological conditions and their low uptake by cells. Most of the improvements in the design of nucleic acid derivatives aim to enhance stability to nuclease and improve cell uptake without affecting the hybridisation properties, which are vital for the efficient inhibitory properties of oligonucleotides. A large number of nucleic acid derivatives have been developed [5, 7] . The conjugation of lipids to oligonucleotides, such as cholesterol [8, 9] , produces molecules with improved inhibitory properties [10, 11] .
Oligonucleotide-peptide conjugates are chimeras of oligonucleotides and peptides which are produced to embed some of the biological or biophysical properties of peptides to oligonucleotides. Reacting oligonucleotides with polylysine [12] , basic [13, 14] , fusogenic [15, 16] and signal peptides [17, 18] has produced new compounds with improved cellular uptake profiles.
Peptide-oligodeoxynucleotide conjugates are prepared through distinct conjugation chemistries which include stable or cleavable linking units (linkers). In the post-synthetic conjugation approach, the two moieties are prepared independently on solid-phase and thiols and maleimido groups are especifically introduced to link the two molecules [17, 19] . In the stepwise approach, oligonucleotide-peptide conjugates are prepared by combining amino acids and nucleobases using solid-phase protocols on the same solid support [16, [20] [21] [22] . In the latter case, one of the main challenges is the incompatibility or efficiency of protection-deprotection protocols. For example, at the end of the solid-phase peptide synthesis an acid treatment is usually required, yet this can lead to partial DNA depurination. In the synthesis of oligonucleotide 3 -peptides, this undesired complication can be prevented by using Boc-protected amino acids with Fm or Fmoc groups for the protection of side chains, a base-labile linker and standard phosphoramidites [16, 20, 21] .
In the RNA interference field, cationic cell-penetrating peptides such as TAT-peptide and penetratin, facilitate the cell uptake of siRNA [23] [24] [25] [26] [27] [28] . A particulary successful result was obtained with a peptide derived from the glycoprotein of the rabies virus [23] . The incubation of this peptide, which carryies a polyarginine tail with siRNA, produced a complex that facilitates the delivery of siRNA to the central nervous system [23] . Most of the results obtained to date using peptides and siRNA were either not covalently linked to RNA or covalently linked by the post-synthetic conjugation method. Solid-phase protocols for the preparation of aminoacyl-tRNA fragments have been described [29, 30] ; however, to our knowledge there are no data on the preparation of RNA-peptide conjugates for RNA interference studies using the stepwise approach.
Here we describe the stepwise synthesis of oligoribonucleotides carrying nuclear localization peptide sequences. Tumor necrosis factor (TNF-α) was selected as a target as this protein is a major mediator of apoptosis as well as inflammation and immunity. Furthermore, TNF-α has also been implicated in the pathogenesis of many human diseases and consequently the inhibition of this cytokine is of particular relevance.
Experimental section

Oligonucleotides
The following RNA sequences were obtained from commercial sources (Sigma-Proligo, Dharmacon): sense or passenger scrambled 5 -CAGUCGCGUUUGCGACUGG-dT-dT-3 , antisense or guide scrambled 5 -CCAGUCGCAAACGCG-ACUG-dT-dT-3 , antisense or guide anti-TNFα: 5 -GAG-GCUGAGACAUAGGCAC-dT-dT-3 and sense or passenger anti-TNFα: 5 -GUGCCUAUGUCUCAGCCUC-dT-dT-3 . RNA monomers in capital letters, dT represents 2 -deoxythymidine. The 3 -cholesterol passenger anti-TNFα: strand 5 -GUGCCUAUGUCUCAGCCUC-dT-dT-3 -cholesterol was prepared using the cholesterol-tetraethyleneglycol (TEG)-3 -CPG support from commercial sources (Glen Research). The anti-TNFα siRNA has been previously described to efficiently downregulate murine TNFα mRNA [31] .
Synthesis of oligonucleotide-peptide conjugates
Oligonucleotide-peptide conjugates were synthesized by the stepwise approach [32] . The following sequences were prepared: I) 5 -uggauucgu-3 -p-O-(CH 2 ) 5 CONH-N Ala-LysLys-Lys-Lys-Leu-Asp-Lys C -CONH-(CH 2 ) 6 -OH; II)5 CU-GAC-dT-ps-dT-3 -ps-O-(CH 2 ) 5 CONH-N Ala-Lys-Lys-LysLys-Leu-Asp-Lys C -CONH-(CH 2 ) 6 -OH; and III)5 -GUGC-CUAUGUCUCAGCCUC-dT-dT-p-O-(CH 2 ) 5 CONH-N AlaLys-Lys-Lys-Lys-Leu-Asp-Lys C -CONH-(CH 2 ) 6 -OH. The following abbreviations are used: 2 -O-methyl-RNA monomers in low case, RNA monomers in capital letters, dT: 2 -deoxythymidine, p: phosphate, ps: phosphorothioate linkages. Guanosine was protected with the dimethylaminomethylidene group, cytidine was protected with the acetyl group and adenosine with the benzoyl group. The 2 -OH protecting group for the RNA monomers was the t-butyldimethylsilyl (TBDMS) group. Boc-aminohexanol was reacted with succinic anhydride to form the corresponding hemisuccinate [20] , which was reacted with amino functionalized PEG-PS support. The peptide chain was elongated manually using a 5-fold excess of amino acid Boc-protected amino acid and a 5-fold excess of PyBOP and a 10-fold excess of DIEA in DMF for 1 h. Lysine was protected with the Fmoc group and aspartic acid was protected with the Fm group. Once the peptide sequence was completed, the resulting support was reacted with p-nitrophenyl 6-(4, 4 -dimethoxytrityloxy)hexanoate [20] . The addition of this building block introduces an hydroxyl group to the existing peptide. This hydroxyl group is required for the assembly of the oligonucleotide.
The linker was coupled to the peptide-support using PyBOP and DIEA as described above. The unreacted amino groups on the resulting support were blocked with acetic anhydride and DIEA. Oligonucleotides were prepared on a DNA synthesizer (Applied Biosystems 3400) using 2-cyanoethyl phosphoramidites. The following solutions were used: 0.4 M 1H-tetrazol in ACN (activation), 3% trichloroacetic acid in DCM (detritylation), acetic anhydride/pyridine/tetrahydrofurane (1:1:8) (capping A), 10% N-methylimidazole in tetrahydrofurane (capping B), 0.01 M iodine in tetrahydrofurane/pyridine/water (7:2:1) (oxidation). The phosphoramidites were dissolved in dry DCM (0.1 M). A modified cycle was used: Coupling time was increased to 5 min, capping and oxidation times to 1 min, and detritylation time to 2 min (4×30 s). In the synthesis of the 2 -O-methyl-RNA sequence I, the last DMTprotecting group was not removed. In the RNA sequences II and III, the last DMT group was removed because the DMT is partially lost during the fluoride treatment. The average coupling yield was around 97-98% per step for RNA monomers and 99% for 2 -O-methyl-RNA monomers. The solid supports containing the oligonucleotide-peptide conjugates were washed with acetonitrile, treated with a 0.5 M DBU solution in ACN for 5 min, washed with ACN, and dried. The resulting supports were then treated with concentrated aqueous ammonia-ethanol (3:1) for 1 h at 55 • C. The solid supports were filtered, washed with ethanol, and the combined filtrates were evaporated to dryness. Sequences II and III were treated with 0.15 mL of triethylamine.tris(hydrofluoride)/triethylamine/N-methylpyrrolidone (4:3:6) for 2.5 h at 65 • C to remove the TBDMS groups. The reactions were stopped by adding 0.3 mL of isopropoxytrimethylsilane and 0.75 mL of ether. The resulting mixtures were stirred and cooled at 4 • C. A precipitate was formed and then centrifuged at 7,000 rpm for 5 min at 4 • C. The precipitates were washed with ether and centrifuged again. The residues were dissolved in water and the conjugates were purified by HPLC. Analytical HPLC was performed using XBridge TM OST C18 (Waters), 2.5µm, 4.6 × 50 mm column using a 10 min linear gradient from 0% to 35% B, flow rate 1 mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M aqueous TEAA.
Denaturing polyacrylamide gel electrophoreses were performed in a SE-600 Hoefer Scientific apparatus. The gels (8 M urea, 20%, acrylamide/bisacrylamide ratio 19:1), 14 × 16× 0.1 cm in size were run for 5 h at 400 V. Three micrograms of RNA were loaded. The gel was stainned with Stainsall (Sigma).
MALDI-TOF spectra were obtained using a Perseptive Voyager DETMRP mass spectrometer, equipped with nitrogen laser at 337 nm using a 3 ns pulse. The matrix used contained 2,4,6-trihydroxyacetophenone (THAP, 10 mg/mL in ACN/water 1:1) and ammonium citrate (50 mg/mL in water).
Melting experiments
Oligonucleotides (1 µM each) were dissolved in 100 mM potassium acetate, 2 mM magnesium acatate, and 30 mM HEPES-KOH at pH 7.4. The solutions were heated to 90 • C, allowed to cool slowly to room temperature, and stored at 4 • C. UV spectra and melting experiments (absorbance vs. temperature) were recorded in Teflon-stoppered 1-cm path length quartz cells using a spectrophotometer, with a temperature controller and a programmed temperature increase rate of 1 • C/min. Melting curves were run in duplicate at 260 nm. In all cases the complexes displayed sharp, apparently twostate transitions. The data were analyzed by the denaturation curve-processing program.
Cell culture, transfection and cellular assays HeLa cells were cultured under standard conditions (37 • C, 5% CO 2, Dulbecco's Modified Eagle Medium, 10% fetal bovine serum, 2 mM l-glutamine, supplemented with penicillin (100 U/mL) and streptomycin (100 mg/mL). All experiments were conducted at 40-60% confluence. HeLa cells were transfected with 250 ng of murine expressing the TNF-α plasmid using lipofectin (Invitrogen), according to the manufacturer's instructions. One hour after transfection, m-TNF-α expressing HeLa cells were then transfected with 50 nM of siRNA (5 -GUGCCUAUGUCUCAGCCUC-dT-dT-3 /5 GAGGCUGAGACAUAGGCAC-dT-dT-3 , [31] ) against TNF-α using oligofectamine (Invitrogen). The TNF-α concentration was determined from cell culture supernatant by enzyme-linked immunoabsorbent assay kit (Bender MedSystems) following the manufacturer's instructions.
The unmodified siRNA duplex produced 87% inhibition of TNF-α compared with the scrambled siRNA sequence, cholesterol-modified siRNA produced 81% inhibition and nucleoplasmine-modified siRNA produced 89% inhibition (Fig. 3) .
Results and discussion
Synthesis of oligonucleotide-peptide conjugates
Oligonucleotide-peptide conjugates carrying the nucleoplasmine nuclear localization sequence (AKKKKLDK) were synthesized following the stepwise approach. Polyethylenglycol-polystyrene (PEG-PS) was selected as solid support since it gave the best results for the coupling of amino acids and nucleoside phosphoramidites [20, 32, 33] . Scheme 1 shows the outline of the synthesis of the oligonucleotidepeptide conjugates on the same support [20, 32, 33] . To avoid the use of strong acids in the presence of the oligonucleotide, the peptide moeity was first synthesized using the acid-labile Boc group to protect the α-amino function. The protecting groups of the side chain of the amino acids (Fmoc for Lys and Fm for Asp) and the linker of the first aminoacid to the support were base-labile so that they could be removed simultaneously. To this end, the 6-aminohexylsuccinyl (AmHex, [34] ) was used. This linker yields the peptide with an aminohexylamide group at the C-terminal.
Once the peptide was synthesized, the p-nitrophenyl 6-(4, 4 -dimethoxytrityloxy)hexanoate spacer molecule [20] was added to link the oligonucleotide. This molecular spacer introduces an hydroxyl group protected by a DMT group at the N-terminal position of the peptide. After adding the linker, a small 2 -O-methyl-RNA sequence (I: 5 -uggauucgu-3 -p-O-(CH 2 ) 5 CONH-N AKKKKLDK C -CONH-hexyl-OH) was assembled using a slightly modified synthesis cycle and 1H-tetrazole activation. The average coupling yield was around 99% per step. The last DMT group was not removed in order to facilitate the purification of the conjugate by reversed phase HPLC (Fig. 1) . The desired compound was purified in good yield and was characterized by mass spectrometry.
We next studied the assembly of a short RNA sequence (II: 5 -CUGAC-dT-ps-dT-3 -ps-O-(CH 2 ) 5 CONH-N AKKK KLDK C -CONH-hexyl-OH). This sequence contains 5 riboScheme 1 Outline of the synthesis of oligonucleotide-3 -peptide conjugates
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Deprotection and purification nucleotides, 2 thymidine residues (dT) and 2 phosphorothioate (ps) linkages at the 3 -end. These are usual modifications in RNA interference studies. RNA monomers were protected with the t-butyldimethylsilyl (TBDMS) group. The same modified process for the synthesis of the 2 -O-methyl-RNA conjugate was used. In this case the coupling yield was slightly lower 97-98% as a result of the steric hindrance of the TBDMS. The last DMT group was removed before deprotection because partial loss was detected during fluoride treament. For cleavage and deprotection, three consecutive treatments were applied: (I) 0.5 M DBU solution in ACN, (2) concentrate aqueous ammonia-ethanol 3:1 at 55 • C, and (3) triethylamine tris(hydrofluoride) in N-methylpyrrolidone at 65 • C. HPLC purification gave a major product with the expected molecular weight. The yield obtained after purification (5%) was lower than the one achieved in the synthesis of the 2 -O-methyl-RNA conjugate (24%). This difference is attributed to the manipulation steps followed when removing the TBDMS groups. In order to eliminate the excess of fluoride, precipitation of the conjugate with ether is required and this may lower the recovery of the desired conjugate as a result of the small size of the oligomer (7mer). Finally, the 21mer sequence (III) 5 -GUGCCUAUGUC UCAGCCUC-dT-dT-p-O-(CH 2 ) 5 CONH-N AKKKKLDK C -CONH-hexyl-OH was assembled using the same protocol described for sequence II. In this case the desired conjugate was isolated in a 5% after HPLC purification (Fig. 2) . The yield of the 21mer obtained after purification was the same as that of the 7mer but the former was three times longer, thereby indicating a more efficient recovery of the longer conjugate. The purified conjugate was analyzed by HPLC and polyacrylamide gel electrophoresis and characterized by MADI-TOF mass spectrometry.
We examined the effect of the peptide on siRNA duplex stability. The thermal stability of the modified and unmodified duplexes was measured in 100 mM potassium acetate, 2 mM magnesium acetate, and 30 mM HEPES-KOH at pH 7.4. The melting temperature (Tm) of the duplex containing nucleoplasmine was 83.8 • C while the Tm of the unmodified duplex was 83.5 • C. A slightly improved stabilization of the duplex has been described for this peptide on DNA duplexes [32] and it has been attributed to a potential interaction between lysine side chain and DNA phosphates. In the present study two unpaired thymidines separated the peptide from the RNA backbone, therefore it is reasonable to expect no differences between modified and unmodified duplexes.
Inhibition of TNF-α
Oligonucleotide-peptide sequence III was annealed with equimolar amounts of the unmodified guide strand and the resulting duplex was used to inhibit the expression of the TNF-α gene. HeLa cells were transfected first with plasmid expressing murine TNF-α using lipofectin and 1 h later were co-transfected with the siRNA duplex (50 nM) using oligofectamine. After 24 h the amount of TNF-α produced by Figure 3 shows the amount of TNF-α produced after 24 h of transfection of 50nM siRNA unmodified duplexes. Modified and unmodified siRNA against TNF-α produced an 80-90% inhibition of the production of TNF-α compared with the scrambled control siRNA duplex. These results indicate that the introduction of the peptide sequence at the 3 -end of the passenger strand of an RNA duplex does not affect the inhibitory properties of the resulting siRNA duplex in HeLa cells. Further work is required to determine if the presence of the peptide improves the delivery of the siRNA into cells.
In conclusion, we have demonstrated that RNA carrying nucleosplasmine peptide can be synthesized using the stepwise approach. siRNA duplexes covalently linked to the nucleoplasmine peptide can be efficiently delivered to HeLa cells and these conjugates enter the RNAi pathway to silence gene expression as efficiently as unmodified and 3 -cholesterol modified siRNA duplexes.
